Journal
NEUROPSYCHOPHARMACOLOGY
Volume 28, Issue 1, Pages 170-181Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.npp.1300005
Keywords
psilocybin; schizophrenia; model psychosis; serotonin; mismatch negativity; working memory; cognition
Categories
Ask authors/readers for more resources
Previously the NMDA (N-methyl-D-aspartate) receptor (NMDAR) antagonist ketamine was shown to disrupt generation of the auditory event-related potential (ERP) mismatch negativity (MMN) and the performance of an 'AX'-type continuous performance test (AX-CPT)-measures of auditory and visual context-dependent information processing-in a similar manner as observed in schizophrenia. This placebo-controlled study investigated effects of the 5-HT2A receptor agonist psilocybin on the same measures in 18 healthy volunteers. Psilocybin administration induced significant performance deficits in the AX-CPT, but failed to reduce MMN generation significantly. These results indirectly support evidence that deficient MMN generation in schizophrenia may be a relatively distinct manifestation of deficient NMDAR functioning. In contrast, secondary pharmacological effects shared by NMDAR antagonists and the 5-HT2A agonist (ie disruption of glutamatergic neurotransmission) may be the mechanism underlying impairments in AX-CPT performance observed during both psilocybin and ketamine administration. Comparable deficits in schizophrenia may result from independent dysfunctions of 5-HT2A and NMDAR-related neurotransmission.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available